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Abstract
Depression is a common comorbidity in cancer cases, but this is not only due to the emotional distress of having a life-threatening
disease. A common biological mechanism, involving a dysregulated immune system, seems to underpin this comorbidity. In
particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the
development and persistence of both diseases. As a consequence, targeting enzymes involved in this pathway offers a unique
opportunity to develop new strategies to treat cancer and depression at once. In this work, we provide a systematic review of the
evidence up to date on the kynurenine pathway role in linking depression and cancer and on clinical implications of this evidence.
In particular, complications due to chemotherapy are discussed, as well as the potential antidepressant efficacy of novel immu-
notherapies for cancer.
Keywords Cancer . Chemotherapy . Depression . IDO inhibitors . Immunotherapy . Inflammation . Indoleamine
2-3-dioxygenase . Kynurenine
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Introduction
Depression and cancer are both leading causes of death and
disability worldwide, and they often co-occur together, with a
consequent heavy socioeconomic burden. In 2017, it was es-
timated that more than 300million people were suffering from
depression, with rising numbers, as shown in more than 18%
increase in a 10-year range, between 2005 and 2015.
Depression is associated with an increased mortality risk com-
pared to general population (Mols et al. 2013; Cuijpers et al.
2014; Gilman et al. 2017). Indeed, it can lead to death by
suicide, as its worst manifestation. It is widely known that
cancer, with all its subtypes, is one of the biggest challenges
for modern medicine and public health, accounting for around
15–20% of the global annual deaths, with this rate significant-
ly increasing year on year (Wang et al. 2016a). Depression
prevalence rates in cancer patients range from 1% to above
50% (Massie 2004), with differences due to different diagnos-
tic measures used to assess depression (Krebber et al. 2014)
and to cancer type, stage, treatment, and disease course.
Moreover, depression in cancer is difficult to assess, especial-
ly due to the high overlap of neurovegetative symptoms be-
tween these two diseases: for example, fatigue, sleep alter-
ations, and reduced appetite. Despite this variability, it is
now clear that patients with cancer are a population at greater
risk for the development of clinically relevant depressive syn-
dromes, with overall higher prevalence rates than those ob-
served in general population (Miller et al. 2008; Mitchell et al.
2011; Bortolato et al. 2017). Indeed, depression rates are
highest (up to 30–50%) in specific types of cancer, like pan-
creatic, oropharyngeal, and breast cancer (McDaniel et al.
1995) and contribute to worsen the disease course (Sotelo
et al. 2014). On the other hand, evidence suggests that a mood
disorder can precipitate the course of chronic inflammatory
diseases, including cancer (Balon 2006), implying that there
is a bidirectional link connecting cancer and depression.
Despite this evidence, the underlying biological mechanism
linking these two conditions is still unknown.
In the last decades, increasing evidence has been gathered
on the presence of an immune dysregulation in both depres-
sion and cancer (Zalli et al. 2016). As a consequence, it has
been hypothesized that immune activation and inflammation
may play a key role in the pathophysiology of both diseases.
Several studies have explored the inflammatory pathway to
depression. Such pathway appears to partially involve the
communication between peripheral and central immune sys-
tem (CNS). In fact, peripheral inflammatory cytokines have
been shown to affect the brain through different ways
(Cattaneo et al. 2015). This finally results in the activation of
the CNS immune cells, like microglia, the brain resident mac-
rophages. In turn, activated microglia promote central inflam-
mation, which affects neuroplasticity, neurogenesis, and neu-
rotransmitter metabolism, leading to behavioral changes typ-
ical of depression (Brites and Fernandes 2015; Bhattacharya
et al. 2016). Thus, cancer, as well as other chronic diseases,
could lead to the development of depressive symptoms by
inducing inflammatory responses and acting on the immune
signaling to the brain (Pyter et al. 2009; Walker et al. 2013;
Lebeña et al. 2014; Yang et al. 2014). In particular, the
kynurenine pathway has been suggested to play a key role in
this process and to be the link between the two diseases.
Despite the relatively recent raising interest, the kynurenine
pathway was first described in the middle of the nineteenth
century, more than 165 years ago. It is the catabolic process in
which tryptophan is converted to kynurenine instead of sero-
tonin. Tryptophan is an essential amino acid, crucial in brain
homeostasis, as it is the precursor to the neurotransmitter se-
rotonin and the hormone melatonin. However, the major route
for tryptophan catabolism in mammalian cells is the
kynurenine pathway. In this pathway, tryptophan is converted
to kynurenine and is degraded leading to the production of
nicotinamide adenine dinucleotide (NAD+) as the end prod-
uct, which is necessary for energy production. Kynurenine
and its further breakdown products are globally called
Bkynurenines.^
The first step of the process is catalyzed by two heme-
dependent enzymes: tryptophan 2,3 dioxygenase (TDO) and
indoleamine 2,3 dioxygenase (IDO) (1 and 2). TDO is pre-
dominantly expressed in the liver tissue, while IDO is diffused
in most of the tissues in the human body. This last enzyme
seems to be an important link between the kynurenine path-
way and inflammation, because of its activation by pro-
inflammatory cytokines. Proceeding through the metabolic
cascade, another dioxygenase (3-hydroxyanthrenilic acid
dioxygenase (HAO)) creates a compound (alpha-amino-be-
ta-carboxymuconate-epsilon-semialdehyde) which decays
non-enzymatically to quinolonic acid (QUIN), a NAD+ pre-
cursor. Another critical enzyme for QUIN production is
kynurenine 3-monooxygenase (KMO).
It has been demonstrated that QUIN can selectively acti-
vate glutamate N-methyl-D-aspartate (NMDA) receptors and
its accumulation could result in excitotoxicity to the neurons
and disturb the glutamatergic transmission (Bender and
McCreanor 1985). In an alternative pathway to the NAD+
production, QUIN can be converted into kynurenic acid
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(KYNA), which is demonstrated to be neuroprotective,
counteracting the effects of QUIN. So, there is a balance be-
tween neurodegenerative and neuroprotective effects in the
kynurenine pathway, expressed by the QUIN/KYNA ratio,
which is strictly related to immune activation. This process
involves the microglia and the astrocytes cells, which are the
primary site for tryptophan catabolism in CNS. KYNA is
mainly produced by astrocytes, while microglia are responsi-
ble for QUIN production. QUIN/KYNA, as well as the most
used kynurenine to tryptophan ratio (K/T ratio), could be used
as a measure of the pathway activity.
As mentioned above, the kynurenine pathway is strictly
related to the immune response. Evidence suggests that in-
flammation significantly shifts tryptophan metabolism to
kynurenine production, carrying out several biological func-
tions. An increased kynurenine pathway activity may there-
fore be associated with various clinical conditions linked to
immune activation, such as depression and cancer. Hence, it is
conceivable that the kynurenine pathway could represent one
of the links between depression and other clinical conditions
such as cancer, even though the mechanisms are not always
clear and still not completely understood. Thus, an overview
of the current evidence on this topic and its clinical implica-
tions is needed.
The aim of this paper is to investigate the scientific evi-
dence to date on the role of the kynurenine pathway in linking
depression and cancer. While the background information on
the kynurenine pathway and on the comorbidity between de-
pression and cancer has been provided as a narrative review,
we adopted a systematic approach to identify all the clinical
and preclinical studies analyzing kynurenine pathway as a
biological link between depression and cancer. We also con-
sider the clinical implication of such association in terms of
treatment strategies and we discuss the effects of current med-
ications and of potential new therapeutic agents.
Kynurenine pathway in depression
The limits of monoaminergic psychopharmacological thera-
pies are well known to clinical practitioners. Treatment-
resistant depression (TRD) is a high prevalence event, with
rates of 12%–20% (Mrazek et al. 2014). This suggests that
other factors than monoamine depletion could contribute to
the pathogenesis of depression. As a consequence, in the last
decades, alternative etiologies of major depressive disorder
(MDD) have been investigated in order to identify new poten-
tial treatment targets (Réus et al. 2015), such as the immune
system.
Compelling evidence suggests that inflammatory patterns,
including abnormalities of the kynurenine pathway, may be
implicated in the pathophysiology of depression (Savitz
2017). Animal models have shown that depressive-like
behavior is associated with an increased inflammation and
increased IDO activity (O’Connor et al. 2009; Norden et al.
2015). A similar association has been found in humans, where
the kynurenine pathway activation has been associated with
the development of depressive symptoms, and with symptoms
severity. For example, QUIN/KYNA ratio is higher in de-
pressed patients than in healthy controls (Myint 2012), sug-
gesting an imbalance of kynurenine metabolites towards neu-
rodegenerative effects. A study from Savitz et al. (2015b)
indicates that these abnormalities persist also in the remission
phase of MDD patients, diagnosed according to Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV-TR).
A recent meta-analysis (Ogyu et al. 2018) revealed that de-
pressed patients have decreased KYNA levels compared with
healthy controls, while no difference was found in the levels
of QUIN. Interestingly, they found increased QUIN levels,
together with decreased KYNA levels, in antidepressant-free
patients compared with healthy controls. Therefore, monoam-
inergic antidepressants, as well as other treatments such as
omega-3 fatty acids, could exert their antidepressant activity
by reducing kynurenine pathway–related neurotoxicity
(Borsini et al. 2017). In terms of symptom domains, Hestad
and colleagues (Hestad et al. 2017) showed K/T ratio to be
particularly useful, given the specific association between el-
evated K/T ratio and poorer cognitive performance in
depression.
A long-lasting and/or uncontrolled immune activation, as
observed in multiple chronic diseases, has been associated
with clinically relevant behavioral symptoms, such as depres-
sion (Capuron and Miller 2011), and the kynurenine pathway
appears to be strictly implicated in this association. Indeed,
there is vast evidence linking clinical conditions characterized
by a chronic immune response (such as hepatitis C, autoim-
mune disorders, cardiovascular diseases, diabetes, and cancer)
to the activation of the kynurenine pathway (Oxenkrug 2013;
Walker et al. 2013; Sperner-Unterweger et al. 2014).
Consequently, the kynurenine pathway could hypothetically
mediate the development of depressive symptoms in the
above-mentioned conditions. Hepatitis C is largely related to
depressive symptoms, with very high depression prevalence
rates. However, these data are influenced by cytokine immu-
notherapy, such as interferon (IFN)-alpha, that could in turn
frequently cause depression (Schaefer et al. 2012), as
discussed in the later section on BImplication for
intervention.^ Alterations of the kynurenine pathway could
also mediate sleep disturbance, which is associated with ele-
vated QUIN/KYNA ratio and increased C-reactive protein
(CRP), as showed by Cho and colleagues in their interesting
clinical study on depressed patients (Cho et al. 2017). In ad-
dition, several genetic alterations of the enzymes involved in
this pathway have been identified and have been proposed to
be associated with MDD, especially polymorphisms of the
genes encoding IDO1/2 and KMO (Boros et al. 2018).
Psychopharmacology
Finally, alterations of the kynurenine pathway were studied
also with neuroimaging techniques. Magnetic resonance im-
aging (MRI) studies in depressed patients (identified accord-
ing to DSM-IV-TR criteria) showed reductions in cortical
thickness in depressed patients compared with healthy con-
trols, particularly in right medial prefrontal cortex (mPFC),
together with increased QUIN/KYNA ratios (Meier et al.
2016). Moreover, in MDD patients, kynurenine and K/T ratio
were inversely associated with the total striatal volume, de-
fined as the sum of the volumes of the nucleus accumbens,
caudate, and putamen (Savitz et al. 2015a).
Nonetheless, there are discrepancies that should be taken
into account. Indeed, some studies showed no correlation or
even a negative correlation between kynurenine pathway ac-
tivity and depression. Dahl and colleagues (Dahl et al. 2015)
found no increase in kynurenine pathway plasma markers in
patients with a depressive episode, assessed with DSM-IV
criteria and the Montgomery–Åsberg Depression Rating
Scale (MADRS, total score ≥ 20), compared with healthy con-
trols. The kynurenine pathway was unaltered after a 12-week
antidepressant treatment, which significantly reduced symp-
toms scores. Similarly, Baranyi and colleagues (Baranyi et al.
2017) did not find any difference in kynurenine and QUIN
concentrations in depressed subjects compared with healthy
controls. Still, they found lower KYNA concentrations in de-
pressed patients, partially confirming the results discussed
above. In a recent study, kynurenine levels and K/T ratio were
actually decreased in MDD medication–free patients, again
diagnosed according to DSM-IV criteria; interestingly,
kynurenine levels were increased after 8 weeks of antidepres-
sant treatment (Umehara et al. 2017). However, no informa-
tion on the other metabolites was collected. Some data also
suggest that the inflammatory phenotype present during de-
pression might be independent from kynurenine pathway ac-
tivation and IDO expression (Hughes et al. 2012). Similarly,
depressive symptoms during inflammation might develop in-
dependently from tryptophan degradation (Quak et al. 2014).
As Arnone and colleagues suggest in their interesting system-
atic review and meta-analysis (Arnone et al. 2018), such con-
flicting results may be due to various clinical variables and
confounders, like age, sex, and metabolic status of partici-
pants, as well as illness severity, antidepressant treatment,
study design, and power calculation. The lack of direct mea-
surements of central inflammation, including kynurenine
pathway markers, complicates even more our understanding
of this relationship. Of note, it should be considered that de-
pression during chronic inflammatory conditions could be eti-
ologically different from other depressive disorders (Arnone
et al. 2018) and that kynurenine pathway alterations could be
present only in the specific subgroup of depressed patients
with immune comorbidities (Miller and Raison 2016).
In conclusion, the majority of studies to date suggest that an
overactivation of the kynurenine pathway might be an
important intersection point between genetic and environmen-
tal factors involved in the pathophysiology of depression
(Oxenkrug 2010). Moreover, IDO activity may be a valid
target for new antidepressant treatments. However, it seems
clear that additional and more tailored research is needed to
strengthen our knowledge.
Kynurenine pathway in cancer
Given the importance of tryptophan metabolism and
kynurenine pathway in driving inflammatory responses, it is
not surprising that the kynurenine pathway has recently
emerged as an important factor in the pathogenesis of many
types of cancer. In addition, tryptophan metabolism is also
critical for cell proliferation and immunoregulation. What is
still unclear is whether the kynurenine pathway in cancer is
activated by the biology of the disease (for example inflam-
matory processes) or simply by the related stress. However, its
role in tumorigenesis needs particular attention and has been
highlighted by several findings.
First, recent evidence suggests that IDO activity may sup-
port the tumor escape from the immune system (Gostner et al.
2015). There are two types of IDO enzyme, IDO1 and IDO2,
that convert tryptophan to kynurenine, with different activity
rates. IDO2 is less expressed and has a weaker enzymatic
activity than IDO1. IDO1 activity is strictly related to two
key inflammatory cytokines, interferon-gamma (IFN-
gamma) and interleukin 6 (IL-6), whose function in inflam-
mation and in cancer is widely known even if not completely
understood: the first one has a prevalent anti-tumoral effect,
the second one is mainly a pro-tumorigenic factor. IFN-
gamma activates IDO1 expression, which in turn activates
IL-6, creating a network where IDO1 acts like a negative
feedback on IFN-gamma, and partially upregulates IL-6.
Being a regulatory interface between IFN-gamma and IL-6,
IDO1 promotes a pro-inflammatory response that plays a role
in cancer neovascularization, by enhancing new blood vessel
development (Prendergast et al. 2017). More importantly, this
enzyme seems to promote tumor progression, by predomi-
nantly acting on regulatory T cells (Tregs), effector cytotoxic
CD8+ T cells (Teff), and natural killer cells (NK) (Munn and
Mellor 2016); these lymphocytes exert a protective activity by
reducing tumor progression and improving antitumor immu-
nity, but kynurenine can suppress CD8+ T and NK cells and
bias Tregs differentiation (Muller et al. 2018). This activity is
proved to be reversible by administration of a therapeutic en-
zyme, PEGylated kynureninase, that degrades kynurenine to
an immunological inert compound, with a related marked in-
crease in proliferation of CD8+ lymphocytes, that in turn pro-
mote tumor infiltration (Triplett et al. 2018). Although less
studied, IDO2 has been found to be overexpressed in some
human tumors, to functionally enable IDO1-dependent Treg
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suppression (Metz et al. 2014), and to underpin B cell–
mediated autoantibody production (Merlo et al. 2016), which
is important in the development of certain cancers, such as
squamous cell carcinomas (Prendergast et al. 2017).
Together, the IDO1 and IDO2 genes are variably upregulated
in neoplastic cells as well as in stromal, endothelial, and innate
immune cells of the tumor microenvironment and in tumor-
draining lymph nodes.
Data are available also on the other tryptophan-
catabolizing enzyme, TDO, that is constitutively expressed
in the liver and responsible for metabolizing dietary trypto-
phan. TDO is also activated during cancer. From recent find-
ings, gene expression levels of TDO2, the gene encoding
TDO, correlate with poorer breast cancer clinical outcomes
(Greene et al. 2018). All together, these findings suggest that
new pharmacologic agents may target both IDO (1 and 2) and
TDO.
The dysregulation of the kynurenine pathway in cancer
may also promote malignancy by NAD+ production, which
could directly affect several cellular functions. Furthermore,
NAD+ can activate the transcription factor aryl hydrocarbon
receptor (AhR) and consequently regulate gene expression
(Bostian and Eoff 2016).
An interesting study by Schroecksnadel et al. (2007) ana-
lyzed 146 patients suffering from a various kind of malignan-
cies (mainly gastrointestinal tumors, hematological malignan-
cy, gynecological neoplasms, and lung cancer). Fifty-four sub-
jects were depressed and had to take antidepressant medica-
tion. Enhanced tryptophan degradation, measured by lower
tryptophan levels and increase in kynurenine concentrations
and K/T ratio, was related to a diminished quality of life
(QoL), assessed by self-reported scores (from 1 to 5). This
result emphasizes the role of immune-mediated tryptophan
degradation in cancer-induced QoL deterioration, but, surpris-
ingly, QoL was not significantly associated with depression.
Nonetheless, the study did not directly measure depression
status or antidepressant medication in relation to kynurenine
pathway, leaving some questions open for future research.
Finally, plasma biomarkers of inflammation and
kynurenine pathway activity are independent predictors of
mortality due to cancer and the latter can be used as a prog-
nostic factor (Zuo et al. 2016). In particular, even at the early
stage of cancer, IDO activity is enhanced (Lyon et al. 2011)
and such activity, in the vast majority of studies, has been
associated with a poorer prognosis (Godin-Ethier et al. 2011;
Gostner et al. 2015). Moreover, IDO activation may be linked
to the development of cancer-related fatigue and thus to its
debilitating consequences (Kim et al. 2015).
In their study on women with breast cancer, Lyon and col-
leagues (Lyon et al. 2011) found significant differences in
tryptophan degradation, expressed in an enhanced IDO activ-
ity, between patients with early-stage breast cancer and
healthy controls. One important consideration from the
authors is that this could be relevant to the development of
neuropsychiatric symptoms, including depression. As it is
quite clear that tryptophan metabolism is critical in both de-
pression and cancer, the assumption that in patients suffering
from various types of cancer the development of depression
might be associated to immune activation, especially to
immune-mediated IDO activation, has gained more and more
attention (Kurz et al. 2011). However, this hypothesis remains
quite understudied. In Table 1, we have briefly summarized
cancer types where alterations in kynurenine pathway have
been demonstrated, together with prevalence rates of depres-
sion, assessed via diagnostic interviews or by self-reported
questionnaires.
Methods
A systematic review was performed using PubMed,
PsycINFO, Ovid MEDLINE ®, Embase, CINAHL, and
ScienceDirect searches through December 2018. We searched
for combinations of the following MeSH search terms: 1st
category: Bkynurenine^ or Bkynurenine pathway^; 2nd cate-
gory: Bcancer^ or Bneoplasm^ or Btumor^; 3rd category:
Bdepression^ or Bdepressive disorder^ or Bmood disorder.^
As explained in the flowchart (Fig. 1), the electronic search
returned 457 records containing at least one term from each
category. We identified 279 papers, excluding duplicates. We
screened all titles and abstract; we excluded reviews, confer-
ence abstracts, notes, comments, letters, editorials, chapters,
and books; and we included only English language published
data papers. We then assessed 108 full-text data articles for
eligibility. We retrieved the studies if they met the following
inclusion criteria: (1) specifically measure kynurenine path-
way alterations; (2) examine an animal or human sample of
subjects with cancer; and (3) directly assess depression or
depressive-like behavior. As a result, we finally reported ten
studies specifically examining this relationship, listed in
Table 2.
Is kynurenine pathway the potential link
between depression and cancer?
We have searched for both preclinical and clinical evidence of
the role of the kynurenine pathway in linking depression and
cancer. In particular, we investigated how the tryptophan
shunt towards formation of kynurenine could be a key patho-
physiological mechanism in the development of depressive
symptoms during cancer.
An animal study on adult mice with a model of tumor
growth (colon adenocarcinoma) was carried out by Norden
and colleagues (Norden et al. 2015). They confirmed a
neuro-inflammatory state associated with cancer and depres-
sion. In particular, tumor-bearing mice showed increased
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brain expression of pro-inflammatory cytokines, tumor-
induced fatigue, and depressive-like behaviors. However,
tryptophan metabolism was found not to be significantly al-
tered, with no differences in IDO and only slight increases in
KMO expression. Moreover, fluoxetine administration at a
relatively low dose (3 mg/kg/day) in tumor-bearing mice re-
duced depressive-like symptoms, with no effect on tumor
growth, muscle wasting, fatigue behavior, or cytokine and
kynurenine pathway enzymes expression in the brain, sug-
gesting that depressive symptoms may be treated as indepen-
dent. It is still not excluded that administration of fluoxetine
may act upstream in the pathway, by altering pro-
inflammatory cytokine expression in the brain. In fact, previ-
ous studies have shown anti-inflammatory effects of fluoxe-
tine by decreasing pro-inflammatory cytokines (Baumeister
et al. 2016), with also a direct effect on the brain (Lim et al.
2009), supporting the need for further research.
As far as human studies are concerned, pancreatic cancer is
known to have a particularly high prevalence rate of depres-
sion (Breitbart et al. 2014, Table 1), and so, it is one of the
most studied. A case report was recently presented by Barnes
et al. (2018) on a patient with pancreatic adenocarcinoma and
a new-onset clinically assessed severe depression. The authors
found markedly elevated levels of IDO1, IDO2, and TDO in
patient’s resected tumor specimen. It has been hypothesized
that kynurenine pathway is a biological basis for development
of depression in this specific malignancy, together with alter-
ations of other inflammatory pathways (Bettison et al. 2018).
A study was conducted to specifically test this hypothesis
(Botwinick et al. 2014), in which 17 patients with pancreatic
adenocarcinoma were recruited and assessed for the presence
of depressive symptoms, measured with the Beck Depression
Inventory (BDI) scale. Findings indicated a negative correla-
tion between mood scores and the plasma ratio between
KYNA (already mentioned to have a neuroprotective effect)
and tryptophan (KATR), while a positive correlation was
found between tumor extension (tumor size and nodal in-
volvement) and plasma kynurenine levels. The correlation
between KATR and depression scores remained significant
after controlling for the percentage of positive lymph nodes
and maximal primary tumor diameter. Thus, the production of
kynurenines (IDO metabolites) seems to be involved in the
pathway between pancreatic cancer and depression, although
a properly causal relationship is not demonstrated.
Table 1 Kynurenine pathway in cancer and rates of depression
Type of cancer Kynurenine pathway alterations Studies (for kynurenine pathway alterations) Depression
prevalence rates
Oropharingeal cancer High IDO expression Laimer et al. 2011 22–57%1–2
Pancreatic cancer High IDO1 expression, high K/T ratio Santhanam et al. 2016; Zhang et al. 2017;
Huang et al. 2018
33–50%1–2
Breast cancer High IDO and TDO expression Lyon et al. 2011; Isla Larrain et al. 2014;
Heng et al. 2016; Greene et al. 2018
1.5–46%1–2-3
Brain tumors Increased IDO activity (high K/T ratio and
QUIN/KYNA ratio)
Adams et al. 2014; Bostian and Eoff 2016 15–44%4–5
Lung cancer High IDO expression, TDO2 activation Hsu et al. 2016; Tang et al. 2017 3–44%2–3
Thyroid carcinoma High IDO1 expression Moretti et al. 2014 up to 36%5
Gynecological cancer Increased IDO activity (high kynurenine
and K/T ratio)
De Jong et al. 2011 12–26%1–2-3
Gastrointestinal cancer High IDO1 expression Santhanam et al. 2016 11–25%1–2
Hematological malignancies High IDO expression Hourigan and Levitsky 2011 1–25%1–2-3
Kidney cancer High IDO1 expression, high K/T ratio Van Gool et al. 2008; Lucarelli et al. 2017;
Trott et al. 2016
6–24%5–6
Melanoma High IDO and TDO expression Capuron et al. 2003; Meng et al. 2017;
Pilotte et al. 2012
4–20%3–7
Prostate cancer High IDO expression Feder-Mengus et al. 2008 15–19%8
1 (McDaniel et al. 1995)
2 (Massie 2004)
3 (Krebber et al. 2014)
4 (Richter et al. 2015)
5 (Hartung et al. 2017)
6 (Thekdi et al. 2015)
7 (Kasparian 2013)
8 (Watts et al. 2014)
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As we discussed, the role of immune activation in linking
depression and cancer was hypothesized also in other types of
cancer, such as breast cancer (Lyon et al. 2011). A clinical
study assessed the levels of tryptophan metabolites in a sam-
ple of 154 subjects divided in 4 subgroups: suffering from
breast cancer, depression, both, or neither (Hüfner et al.
2015). In breast cancer patients, depression was diagnosed
assuming a ≥ 8 cutoff at the Hospital Anxiety and
Depression Scale (HADS) or an ongoing treatment with anti-
depressant medications, while non-breast cancer patients were
clinically diagnosed as depressed according to International
Classification of Diseases (ICD-10) criteria. Significantly
higher neopterin levels (considered as a marker of cellular
immune system activation) were found in patients suffering
from depression and anxiety, suggesting a pro-inflammatory
state of type 1 T helper lymphocytes (Th1). Moreover, K/T
ratio was significantly associated with breast cancer, state anx-
iety, and their interaction, with highest values in patients suf-
fering from both conditions. Finally, the phenylalanine/
tyrosine ratio, considered a measure of inflammation
(Wannemacher et al. 1976), was higher in the comorbid cancer
and depression subgroup. Interestingly, an excess of phenyl-
alanine could interfere with serotonin production by compet-
ing with tryptophan for the same active transport channel to
cross the blood-brain barrier (Linden et al. 2016). In a different
study conducted in 61 breast cancer patients (Pertl et al. 2013),
the authors did not find an association between kynurenine
pathway alterations and depressive symptoms, assessed here
Identification                                                                                                        Excluded
I
Screening
Excluded
Eligibility
Excluded
Included
279 records screened 
457 records identified 
108 full-text data articles assessed for 
eligibility
3 articles with no 
depression/depressive-like 
behaviour assessment
10 Studies included in systematic review
178 duplicate records
102 reviews
49 conference abstracts
8 notes, comments, letters, or 
editorials 
6 books or chapters
6 records not published in 
English
92 articles with no sample subjects 
with cancer
3 articles with no kynurenine 
pathway direct measurement
Fig. 1 Systematic review
flowchart
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too with HADS score, before chemotherapy. Still, such alter-
ation of the pathway was found to be related to cancer treat-
ment, as we will discuss below in the section BImplication for
intervention.^
Finally, we have already mentioned neuroimaging alter-
ations due to kynurenine pathway activation in depressed pa-
tients (Savitz et al. 2015a; Meier et al. 2016). Further analyses
were performed more specifically in cancer-related depres-
sion. Bosnyák and colleagues utilized 11C-alpha-methyl-L-
tryptophan (AMT)-positron emission tomography (PET)
scanning on 21 patients with brain tumor without a previous
history of clinical depression, assessing the presence of de-
pressive symptoms through BDI scores. Seven patients
showed clinical levels of depression (BDI score > 13) with
associated abnormalities of tryptophan transport and metabo-
lism. As the authors suggest, these modifications indicate a
possible imbalance between the serotonin and kynurenine
pathways. Moreover, this could serve as a molecular imaging
marker of brain tumor–associated depression (Bosnyák et al.
2015).
Potential confounders in this association
Despite this evidence, the symptoms overlap between cancer
and depression could bias the assessment of depressive symp-
toms in oncologic patients, as we mentioned above, leading to
misdiagnose depression. On the other hand, many biological
modifications strictly related to cancer, such as the increased
energy demand, or the biological impact of cancer treatments,
could be a trigger for the development of neurovegetative
symptoms, regardless of kynurenine pathway activation and
the presence of clinical depression.
We already discussed that symptoms like fatigue in onco-
logic patients could be associated with kynurenine pathway
activation (Kim et al. 2015; Norden et al. 2015). However,
their precise etiological and pathophysiological mechanisms
are still unknown. Even though it is conceivable a crucial role
of inflammation, they could also involve other factors in a
complex interaction between immune, endocrine, and nervous
systems (Berger et al. 2015; Saligan et al. 2015). Interestingly,
energy demand and fatigue, although obviously related,
should be considered as distinct symptoms (Eshragh et al.
2017), suggesting that several different factors contribute to
the development of neurovegetative symptoms during cancer.
In addition, it should be considered that cancer and cancer
therapy could very often be related to significant levels of
stress. In this regard, it has been demonstrated that stress is,
in turn, associated with kynurenine pathway activation
(O’Farrell and Harkin 2017) through interactions between
the autonomic nervous system and the immune system (Won
and Kim 2016). Even stress could therefore contribute to the
relationship investigated in this paper. Thus, there is a vast
variety of symptoms and clinical conditions, all connected to
each other, that could be related directly or indirectly to the
kynurenine pathway activation and hence to its consequences.
Accordingly, we believe that an accurate diagnosis of clinical
depression with validated and replicable tools is crucial to
disentangle the different contribution of cancer and depression
to the overall clinical picture and to better understand the
underlying mechanism of such comorbidity. We will debate
below the additional confounding effects of chemotherapy.
The results we discussed confirm an alteration in the
kynurenine pathway in both cancer and depression, with also
evidence of a mutual interaction. However, a potential role of
such alteration in causing depressive symptoms during cancer
is still uncertain, due to discrepancies between the results, and
the paucity of studies.
Implication for intervention
IFN-alpha treatment
Although it represents today only a marginal treatment for
hepatitis C, the IFN-alpha therapy is still used for the treat-
ment of renal cancer and melanoma, and it is the perfect evi-
dence of a cancer therapy that challenges the immune system
just like cancer itself. As a consequence, IFN-alpha therapy
can lead to depression. Indeed, IFN-alpha therapy is widely
known to be associated with high rates of psychiatric side
effects, particularly depressive symptoms (Felger et al. 2016;
Hepgul et al. 2016).
Again, this relationship could be due to an over-stimulation
of kynurenine pathway, especially via IDO activation, caused
by inflammatory cytokines (Russell et al. 2018). A preclinical
study by Fischer et al. (2015) found that IFN-alpha adminis-
tration induced depressive symptoms (measured with the
forced swim test) in rats and an increased K/T ratio.
However, while imipramine administration seemed to im-
prove depressive-like behavior without acting on the
tryptophan-kynurenine pathway, treatment with celecoxib
Table 2 List of studies specifically examining the role of the
kynurenine pathway in linking depression and cancer
Author Type of study Type of cancer
Bannink et al. 2007 Clinical study Melanoma; renal cell carcinoma
Barnes et al. 2018 Case report Pancreatic adenocarcinoma
Bosnyák et al. 2015 Clinical study Brain tumor
Botwinick et al. 2014 Clinical study Pancreatic adenocarcinoma
Capuron et al. 2003 Clinical study Malignant melanoma
Hüfner et al. 2015 Clinical study Breast cancer
Lyon et al. 2018 Clinical study Breast cancer
Norden et al. 2015 Animal study Colon adenocarcinoma
Pertl et al. 2013 Clinical study Breast cancer
Van Gool et al. 2008 Clinical study Renal cell carcinoma
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seemed to reverse both depressive symptoms and the K/T
ratio. Similarly, in a study on patients with malignant melano-
ma treated with IFN-alpha, Capuron and colleagues (Capuron
et al. 2003) demonstrated that patients developing depression,
diagnosed according to DSM-IV criteria, showed greater in-
creases in kynurenine, neopterin, and K/T ratio. In these pa-
tients, the SSRI antidepressant paroxetine could attenuate the
behavioral consequences of IFN-alpha by acting more on the
tryptophan availability than on kynurenine or neopterin re-
sponse. These findings suggest that, despite the psychiatric
side effects commonly related to IFN-alpha treatment could
be mediated by an activation of the kynurenine pathway, ther-
apy with antidepressant may not be effective on this pathway,
but rather improve depressive symptoms in other ways.
However, there are also studies disconfirming the link be-
tween the kynurenine pathway activation induced by IFN-
alpha and the onset of depression. It has been reported that
cancer patients treated with IFN-alpha exhibited an activation
of the kynurenine pathway with consequent depletion of tryp-
tophan levels. IFN-alpha treatment was found to alter trypto-
phan metabolism increasing its peripheral degradation, but
this action seemed to be independent from psychiatric side
effects. A study on patients with either melanoma or renal cell
carcinoma found that IFN-alpha treatment altered tryptophan
levels without inducing psychiatric side effects, assessed
through clinical interviews and observer-based rating scales
(MADRS), in addition to a self-reported questionnaire, the
Symptom Check List-90 (SLC-90) (Bannink et al. 2007). In
a further study on patients with renal cell carcinoma, IFN-
alpha action on kynurenine pathway was proved to cause an
imbalance between neurotoxic and neuroprotective metabo-
lites of kynurenine, as seen in an increase in neurotoxic com-
pounds, even though not always related to psychopathological
symptoms, measured by the Mini - In te rna t iona l
Neuropsychiatric Interview (MINI) and the SCL-90 (Van
Gool et al. 2008). These findings may be due to the small
sample sizes in both studies and to differences in cancer types,
and highlight the need for more studies investigating the psy-
chiatric implication of treatment with IFN-alpha in cancer.
Chemotherapy effect on kynurenine pathway
Inflammatory dysfunction is not only related to cancer itself,
but also to its treatment. The improvements in cancer surviv-
ing we have assisted to in the last decades (Jemal et al. 2017)
have not always been followed by an improvement in psychi-
atric comorbidities, like depression, which remain highly
prevalent among cancer patients. It has been hypothesized,
and confirmed by a number of studies, that behavioral symp-
toms in cancer patients could be related to neurotoxic effects
of cancer treatment, especially chemotherapy, in a synergic
action between cancer and its treatment (Wardill et al. 2016;
Santos and Pyter 2018). Indeed, although inflammation, as we
discussed, is pivotal in cancer development (Munn 2017),
several of the most common and widely used chemotherapeu-
tic agents, like cisplatin, paclitaxel, 5-fluorouracil, and doxo-
rubicin, have a demonstrated pro-inflammatory effect (Vyas
et al. 2014). A strong tumor-associated immune response
could be initiated by cancer therapy, and an inhibition of
therapy-induced inflammation may hence improve cancer
outcome (Grivennikov et al. 2010). However, an inflammato-
ry response has not been observed with every chemotherapeu-
tic compound and, to date, studies on the relationship between
chemotherapy and the kynurenine pathway are insufficient
and inconsistent.
Nonetheless, this potential pro-inflammatory effect of che-
motherapeutic agents may lead to development, worsening,
and persistence of depressive symptoms, through the activa-
tion of the kynurenine pathway. This evidence was supported
by Pertl et al. (2013). In their study, the authors did not find
any correlation between depression, assessed using the
HADS, and kynurenine pathway activity before chemothera-
py. Still, they found an enhanced inflammatory activity after
cancer treatment. Moreover, intra-individual changes in pre-
and post-treatment kynurenine levels predicted changes in de-
pression over time, suggesting that increased kynurenine path-
way activation may contribute to depressive symptoms aggra-
vation in patients treated for cancer. Furthermore, alterations
of kynurenine pathway were found after chemotherapy in a
recent pilot study on 19 women with early-stage breast cancer
(Lyon et al. 2018). The authors analyzed global metabolites
post-chemotherapy and observed significantly higher
kynurenine levels and K/T ratios, together with increased
levels of depressive symptoms, assessed again through
HADS score. Nonetheless, neither kynurenine nor tryptophan
levels were associated with depression. These results suggest
that chemotherapy may increase the kynurenine pathway ac-
tivation and contribute to depressive symptoms in patients
treated for cancer, pointing out the indirect effect of chemo-
therapy on maintaining depressive symptoms, even though
the precise mechanism is still unknown and needs further
investigation.
IDO inhibitors
Given IDO crucial role in tumorigenesis and tumor progres-
sion, molecules with the ability to inhibit IDO activity have
increasingly gained attention in immuno-oncology. In partic-
ular, a number of studies are now investigating whether inhib-
itors of IDO1 may improve patient responses to anti-PD1
immune checkpoint therapy in patients with advanced mela-
noma (Muller et al. 2018). Immune checkpoints are molecules
that regulate the immune system by modulating immune tol-
erance and preventing uncontrolled immune responses.
Specific checkpoint inhibitors are therefore emerging as new
pharmacological targets to enhance cancer treatment. In
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particular, PD1 (programmed cell death protein 1) is a cell
surface protein that is involved in immune suppression, and
its ligand (PD-L1) is highly expressed in several cancers
(Francisco et al. 2010;Wang et al. 2016b). Thus, some cancers
use this route to block the immune response and continue
growing. For this reason, PD1 and PD-L1 inhibitors, known
as checkpoint inhibitors, are emerging as a novel immunother-
apy for cancer (Alsaab et al. 2017). An important limit for this
new treatment strategy, however, is that cancer can still main-
tain an immunosuppressive microenvironment by activating
IDO and the kynurenine pathway (Toulmonde et al. 2018).
Consequently, IDO inhibition may be advantageous to im-
prove response rates to anticancer immunotherapies, such as
checkpoint inhibitors.
A large number of molecules to date have been tested as
IDO inhibitors and utilized in clinical trials as anticancer com-
pounds, mainly in combinatorial regimens and in association
with other chemotherapeutic agents, with more promising re-
sults than their administration as a single drug. However, none
of these molecules is up to now approved for clinical use
(Zhang et al. 2018). So far, the most studied molecules are
IDO1 inhibitors, but there has been a recent and rising interest
in IDO2 and TDO inhibitors as well. The 1-methyltryptophan,
a competitive inhibitor of IDO1 (and IDO2) that exists as a
mixture of chiral isoforms (i.e., 1-methyl-D-tryptophan (1-
MDT) also known as indoximod and NLG8189), as well as
second-generation IDO1 inhibitors (such as the orally avail-
able agent epacadostat (INCB024360) and NLG919), and
IDO1-targeting vaccines, were studied clinically and preclin-
ically in cancer patients. So far, other IDO1 inhibitors, includ-
ing 1-methyl-L-tryptophan, methylthiohydantoin tryptophan,
brassinin and derivatives, annulin B and derivatives, and
exiguamine A and derivatives, as well as INCB023843, are
in development (Vacchelli et al. 2014); other drugs include
benzofuranquinones and annulin A analogues (Carvalho
et al. 2014), just to name a few. 1-MDT is probably the most
well studied and it is involved in some encouraging clinical
trials (Godin-Ethier et al. 2011). Up to December 2018, 22
clinical trials involving IDO inhibitors and one involving an
IDO targeting vaccine were ongoing, according to
BClinicalTrials.gov^ results. Most of them were in phase I or
II, four were in phase III. Only three studies, all in phase I,
were evaluating the safety, tolerability, and pharmacokinetics
of a single IDO inhibitor; the others were evaluating the
efficacy of a combination of these compounds with
chemotherapy or immunotherapy, combining them for
example with immune checkpoint inhibitors.
A recent paper raised the question about the real effec-
tiveness of IDO inhibitors, starting from the evidence of
the surprising failure of ECHO-301, a large phase III clin-
ical trial (Garber 2018). The trial involved roughly 350
patients receiving epacadostat (INCB024360), an IDO1-
selective enzyme inhibitor we mentioned above, with
pembrolizumab, an anti-PD1 humanized monoclonal anti-
body, for melanoma treatment. The combination therapy
missed its first primary endpoint of improving overall
survival, compared to pembrolizumab monotherapy.
Nevertheless, this discouraging result should be analyzed
with caution, avoiding definitive judgements. The nega-
tive outcome could reflect uncertainties about particular
aspects of the trial and raises some questions. For exam-
ple, whether the target was adequately inhibited, or if
there was a mechanistic rationale for the combination test-
ed, or again, according to preclinical data, whether a
broader-spectrum approach, inhibiting both IDO and
TDO, would have been better (Muller et al. 2018).
Moreover, other IDO inhibitor molecules, with potential
different chemical properties, could reveal their efficacy
in cancer treatment and other combination therapies will
possibly be refined. The use of this new therapeutic target
may also improve the management of depression during
cancer. However, at this stage of research, the efficacy of
IDO inhibitors in treating both cancer and depression can
only be hypothesized. Indeed, the management of cancer-
related depression still relies on antidepressant, which
may not only enhance monoamine availability, but also
act on inflammatory pathways.
Conclusion
Given the evidence to date, it is conceivable that the
kynurenine pathway may be one of the biological links be-
tween depression and cancer. However, more studies are re-
quired to further analyze the role of kynurenine pathway in the
development of depression in different types of cancer, which
could be related to diverse biological mechanisms. Similarly,
the effect of specific cancer therapies on the development and
persistence of depressive symptoms should be examined in
future research. From a clinical point of view, targeting IDO
activity appears to be a promising treatment approach for can-
cer comorbid with depression. Therefore, not only the anti-
tumoral but also the antidepressant efficacy of IDO inhibitors
should be assessed during future clinical trials.
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